Amicus Therapeutics and Shire Enter Into $440 Million Licensing Agreement

Amicus Therapeutics, Inc. announced that it has entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a subsidiary of Shire plc, to jointly develop Amicus’ three lead pharmacological chaperone compounds for lysosomal storage disorders. Shire will receive rights to commercialize these products outside of the United States. Amicus will retain all rights to commercialize these products in the United States.
PRNewswire